Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: results from the Italian Psocare registry

6533b851fe1ef96bd12a8db3

RESEARCH PRODUCT

Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: results from the Italian Psocare registry

Stefano Piaserico Simone Cazzaniga Sergio Chimenti Alberto Giannetti Mara Maccarone Mauro Picardo Andrea Peserico Luigi Naldi V. Griseta A. Miracapillo M. Azzini L. Mocci M. Michelini A. Offidani L. Bernardini A. Campanati G. Ricotti A. Giacchetti M. Norat F. Gualco A. Castelli A. Cuccia A. Diana G. Roncarolo M. A. Belli M. A. Baldassarre G. Santoro G. A. Vena F. Lo Console R. Filotico V. Mastrandrea B. Brunetti F. Musumeci E. Carrabba P. Dal Mas F. Annicchiarico B. Benvegnã¹ G. Spaziani F. Cusano S. Saletta Iannazzone A. Galluccio M. Pezza L. Marchesi G. Imberti A. Reseghetti C. Barbera M. Reggiani A. Lanzoni A. Patrizi F. Bardazzi A. Antonucci S. De Tommaso R. Balestri W. Wallnofer F. Ingannamorte P. Calzavara-pinton S. Iannazzi C. Zane R. Capezzera S. Bassisi M. T. Rossi V. Altamura W. Vigl C. Nobile N. Aste S. Murgia C. Mugheddu G. Scuderi F. Baglieri C. Di Dio E. Cilioni Grilli C. Mastronardi C. P. Agnusdei A. Antrilli L. Aulisa U. Raimondo G. Scotto Di Luzio V. C. Battarra P. Farro R. Plaitano G. Micali M. L. Musumeci D. Massimino M. Li Calzi S. La Greca M. Pettinato G. Sapienza G. Valenti P. F. De Giacomo D. Dâ€™amico F. Arcangeli D. Brunelli E. Ghetti A. Tulli G. Assi P. Amerio G. Laria F. Prestinari S. Spadafora M. Coppola G. Caresana E. Pezzarossa E. Domaneschi C. Felisi L. Donato M. Bertero L. Musso S. Pa Lazzini P. Bruscino U. C. Agozzino M. Ottaviani C. Simoncini A. Virgili F. Osti P. Fabbri W. Volpi M. Caproni T. Lotti F. Prignano G. Buggiani M. Troiano G. Fenizi A. Altobella A. Amoruso M. Condello A. Goffredo M. G. Righini F. Alessandrini F. Satolli M. Zampetti E. Bertani S. Fossati A. Parodi M. Burlando C. Fiorucci A. Nigro G. Ghigliotti L. Massone G. M. Moise M. Serrai G. Cannata A. M. Campagnoli M. Daly C. Leporati R. Peila G. Filosa L. Bugatti M. Nicolini G. Nazzari R. Cestari F. Anastasio F. M. Larussa N. Pollice F. De Francesco G. Mazzocchetti K. Peris M. C. Fargnoli A. Di Cesare L. De Angelis G. Flati A. S. Biamonte G. Quarta M. Congedo A. Carcaterra D. Strippoli D. Fideli F. Marsili M. Celli M. Ceccarini L. Bachini M. Dâ€™oria V. Schirripa C. De Filippi P. Martini E. Lapucci C. Mazzatenta A. Ghilardi M. Simonacci A. Bettacchi R. Gasco A. Zanca S. Battistini S. Dattola R. Vernaci F. Postorino P. F. Zampieri C. Padovan M. A. Gonzã¡lez Intchaurraga J. Ladurner B. Guarneri S. Cannavo'C. Manfrã F. Borgia A. Puglisi Guerra P. Sedona A. Cattaneo C. Carrera C. Fracchiolla N. Mozzanica L. Prezzemolo S. Menni A. Lodi P. Martino M. Monti L. Mancini F. Sacrini G. F. Altomare M. Taglioni C. Lovati S. R. Mercuri G. Schiesari A. Giannetti A. Conti C. Lasagni M. Greco G. Ronsini S. Schianchi C. Fiorentini S. Niglietta R. Maglietta C. Padalino D. Crippa M. Pini E. Rossi D. Tosi M. Armas V. Ruocco F. Ayala N. Balato F. Gaudiello G. F. Cimmino G. Monfrecola L. Gallo G. Argenziano E. Fulgione G. Berruti S. Ceparano I. De Michele D. Giorgiano G. Leigheb S. Deledda A. Peserico M. Alaibac S. Piaserico L. Schiesari G. Dan I. Mattei E. Oro M. Aricã² M. R. Bongiorno R. Angileri S. Amato F. Todaro M. Milioto R. Bellastro S. Di Nuzzo G. De Panfilis M. Zanni G. Borroni R. Cananzi V. Brazzelli P. Lisi L. Stingeni K. Hansel V. Pierfelice S. Donelli D. Rastelli M. Gasperini P. Barachini R. Cecchi L. Bartoli M. Pavesi S. De Paola M. T. Corradin F. Ricciuti A. Piccirillo L. Viola M. Tataranni M. G. Mautone G. Lo Scocco M. C. Niccoli A. M. G. Brunasso Vernetti G. Gaddoni F. Resta M. C. Casadio M. C. Arcidiaco M. C. Luvarã G. Albertini V. Di Lernia E. Guareschi S. Catrani M. Morri P. Amerio C. De Simone M. Dâ€™agostino I. Agostino S. Calvieri F. Cantoresi A. Richetta P. Sorgi C. Carnevale F. Nicolucci E. Berardesca M. Ardigã² C. De Felice E. Gubinelli S. Chimenti M. Talamonti G. Camplone G. Cruciani F. Riccardi R. Barbati G. Zumiani W. Pagani P. G. Malagoli R. Pellicano D. Donadio C. Di Vito F. Cottoni M. A. Montesu C. Pirodda G. Addis P. Marongiu A. Farris M. Cacciapuoti A. Verrini G. Desirello M. Gnone M. Fimiani M. Pellegrino G. Castelli L. Zappalã G. Sesana V. Ingordo E. Vozza D. Di Giuseppe D. Fasciocco P. Nespoli M. Papini M. Cicoletti M. G. Bernengo M. Ortoncelli A. Bonvicino G. Capella G. C. Doveil M. Forte A. Peroni B. Salomone P. Savoia M. Pippione L. Zichichi M. Frazzitta G. De Luca G. Zumiani L. Tasin D. Simonetto S. Ros G. Trevisan M. Patamia S. Miertusova P. Patrone A. Frattasio F. Piccirillo S. La Spina L. Di Gaetano V. Marzocchi A. Motolese C. Venturi P. Sedona F. Gai S. Pasquinucci R. M. Bellazzi T. Silvestri G. Girolomoni P. Gisondi C. Veller Fornasa G. P. Trevisan

subject

Male primary inefficacy 75% improvement in the Psoriasis Area Severity Index score; PASI; PASI 75; Psoriasis Area Severity Index; TNF; biologics; efficacy; primary inefficacy; psoriasis; secondary loss of efficacy; switching; tumor necrosis factor; tumor necrosis factor-alfa inhibitors; Adult; Analysis of Variance; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Cohort Studies; Confidence Intervals; Dose-Response Relationship Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Immunoglobulin G; Italy; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Proportional Hazards Models; Psoriasis; Receptors Tumor Necrosis Factor; Registries; Retrospective Studies; Risk Assessment; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alpha; Young Adult SWITHCES efficacy TNF psoriasis; psoriasis arthritis; pharmachological treatment PASI 75 Severity of Illness Index Receptors Tumor Necrosis Factor Etanercept Cohort Studies Monoclonal Receptors Settore MED/35 - Malattie Cutanee E Veneree Registries Humanized tumor necrosis factor-alfa inhibitors.switching Hazard ratio Antibodies Monoclonal Middle Aged Treatment Outcome Italy Predictive value of tests 75% improvement in the Psoriasis Area Severity Index score Female Drug Psoriasis Area Severity Index biologic TNF-alpha Adult medicine.medical_specialty tumor necrosis factor Dermatology 75% improvement in the Psoriasis Area Severity Index score; PASI; PASI 75; Psoriasis Area Severity Index; TNF; biologics; efficacy; primary inefficacy; psoriasis; secondary loss of efficacy; switching; tumor necrosis factor; tumor necrosis factor-alfa inhibitors Antibodies Monoclonal Humanized secondary loss of efficacy Risk Assessment Antibodies tumor necrosis factor-alfa inhibitors Drug Administration Schedule Dose-Response Relationship Young Adult Settore MED/35 Predictive Value of Tests Internal medicine Psoriasis Severity of illness medicine Confidence Intervals Humans Psoriasis biologics Adverse effect Psoriasis; TNF-alpha Proportional Hazards Models Retrospective Studies psoriasi biologics; efficacy; primary inefficacy; psoriasis; secondary loss of efficacy; switching; tumor necrosis factor-alfa inhibitors; Adalimumab; Adult; Analysis of Variance; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Cohort Studies; Confidence Intervals; Dose-Response Relationship Drug; Drug Administration Schedule; Etanercept; Female; Follow-Up Studies; Humans; Immunoglobulin G; Infliximab; Italy; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Proportional Hazards Models; Psoriasis; Receptors Tumor Necrosis Factor; Registries; Retrospective Studies; Risk Assessment; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alpha; Young Adult; 2708 Analysis of Variance pharmachological treatment Dose-Response Relationship Drug Proportional hazards model business.industry tumor necrosis factor-alfa inhibitor Tumor Necrosis Factor-alpha PASI Adalimumab Retrospective cohort study psoriasis arthritis medicine.disease Confidence interval Infliximab Surgery Immunoglobulin G Multivariate Analysis ANTI-TNFA business 2708 Follow-Up Studies

description

Background: Some studies have shown that switching patients from one tumor necrosis factor (TNF)-alfa inhibitor to another may be beneficial when they have an inadequate response or an adverse event. Objective: We sought to assess the variables predicting the efficacy of the second TNF-alfa inhibitor in patients discontinuing the first TNF-alfa inhibitor. Methods: Data from all 5423 consecutive patients starting TNF-alfa inhibitor therapy for psoriasis between September 2005 and September 2010 who were included in the Italian Psocare registry were analyzed. Results: In 105 patients who switched to a second TNF-alfa inhibitor who had complete follow-up data, 75% improvement in the Psoriasis Area Severity Index score (PASI 75) was reached by 29% after 16 weeks and by 45.6% after 24 weeks. Patients who switched because of secondary loss of efficacy (loss of initial PASI 75 response) or adverse events/intolerance were more likely to reach PASI 75 than those who switched as a result of primary inefficacy (PASI 75 never achieved) (hazard ratio 2.7, 95% confidence interval 1.3-5.5 vs hazard ratio 2.0, 95% confidence interval 1.0-3.9 and 1, respectively). Limitations: There was a small number of patients with complete follow-up data. Conclusion: PASI 75 response in patients who switched from one antie-TNF-alfa agent to another was significantly reduced in patients who showed primary inefficacy of the first antie-TNF-alfa.

year	journal	country	edition	language
2014-01-01

10.1016/j.jaad.2013.10.019 http://hdl.handle.net/11585/221668